louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06157294: Pulsed Radiofrequency Treatment in Lumbar Facet-Related Pain
Official title: Comparison of the Treatment Outcomes of the Facet Intra-articular Pulsed Radiofrequency and Median Branch Pulsed Radiofrequency Interventions in Lumbar Facet-related Pain
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Facet Joint Pain
Pain Syndrome
Pain, Chronic
Lead sponsor: Başakşehir Çam & Sakura City Hospital
Sponsor class: OTHER_GOV
First posted: 2023-12-05
Enrollment: 116
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Facet joint-related pain is one of the leading causes of low back pain. Facet joint-related disorders can have a negative impact on quality of life and daily living activities, in addition to the pain.Conservative treatment methods such as analgesic medications, physical therapy, and manual therapy are used for facet joint-related low back pain, and interventional pain management practices are used in patients who do not respond adequately to these treatments.

Pulse radiofrequency application, which is a recent popular treatment in interventional pain management, is also frequently applied in the treatment of facet-joint related pain. Pulsed radiofrequency intervention can be applied directly intra-articularly or can be applied to the median branch, which is important structure in pain transmission. Although both methods are frequently used in pain management, there is a lack of information in the literature about which is more effective. This study aimed to compare the treatment results of intraarticular pulse radiofrequency application and median branch pulse radiofrequency application in facet joint-related low back pain.


Eligibility criteria: Inclusion Criteria:

* Having facet joint-related low back pain at least 3 months
* No response to other conservative treatments (analgesic medications, physical therapy, manuel therapy etc.)
* Patients with a pain severity score of at least 6 according to NRS

Exclusion Criteria:

* History of lumbar region surgery
* Patients with bleeding disorders
* Presence of pregnancy and breastfeeding status
* Presence of the infection related findings and any other systemic disorder
* History of allergic reaction to contrast agent
* Patients who do not have sufficient mental function to fill out the scales during the follow-up periods

Primary outcomes:
measure: Change of the pain severity score
timeFrame: Pre-intervention, post-intervention 1th month and post-intervention 6th month
Secondary outcomes:
measure: Change of the disability score
timeFrame: Pre-intervention, post-intervention 1th month and post-intervention 6th month
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Basahsehir Cam and Sakura City Hospital
Study officials:
affiliation: Başakşehir Çam & Sakura City Hospital
name: Burak Erken, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03384394: Evaluating High-flow Nasal Cannula Oxygen Therapy Through LUS During Weaning
Official title: Evaluating High-flow Nasal Cannula Oxygen Therapy Through Lung Ultrasound Score
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: High-flow Nasal Cannula Oxygen
Lead sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Sponsor class: OTHER
First posted: 2017-12-27
Enrollment: 250
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Respiratory distress after extubation is associated with increased morbidity and mortality. Its multifactorial pathophysiology causes a loss of pulmonary aeration during the weaning process, the clinical translation being impaired gas exchange and the occurrence of respiratory distress. Lung ultrasound can accurately quantify the loss of pulmonary aeration before, after end during the weaning trial by calculating the Lung Ultrasound Score (LUS). Investigators have recently demonstrated in a prospective two-center study of 100 patients that the intensity of the lung aeration loss occurring during the weaning trial, was predictive of the development of postextubation respiratory distress within 48 hours following extubation. A LUS ≥ 14 could identify patients at high risk of developing postextubation respiratory distress. A second study that investigators have just completed in 80 patients weaned from mechanical ventilation shows a 30% reduction of respiratory distress in post-extubation High Flow Nasal Cannula oxygen group compared to a standard O2 group.

The establishment of a targeted therapeutic strategy proposed in a group of high-risk patients, defined as having a ≥ 14 LUS at the end of the weaning trial could reduce the incidence of extubation failure and associated morbidity and mortality.


Eligibility criteria: Inclusion Criteria:

* patients above 18, mechanically ventilated on tracheal intubation for more than 48 hours.

Exclusion Criteria:

* Patients with chronic obstructive pulmonary disease (COPD) with moderate to severe (3 and 4) stage defined by a forced expiratory volume in one second (FEV) \<50% of theoretical value
* Patients with previous chronic respiratory disease
* Paraplegia with level\> T8,
* Severe ICU-acquired neuromyopathy
* Patients with tracheostomy for any reason.

Primary outcomes:
measure: To decrease the incidence of extubation failure within 48 hours after a successful spontaneous breathing trial in ICU patients.
timeFrame: 48 hours
Secondary outcomes:
measure: Number of ventilation-free days in ICU following the planned extubation after randomization. - Length of stay in ICU and in-hospital after randomization. - Mortality in ICU and at three months.
timeFrame: treatment in ICU and at three months.
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03132194: Study Comparing Test to Aczone 7.5% and Both to a Placebo Control in the Treatment of Acne Vulgaris
Official title: A Single-center, Double-blind, Randomized, Parallel-group Study, Comparing DPSG to a Placebo Control in the Treatment of Acne Vulgaris
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Acne Vulgaris
Lead sponsor: Taro Pharmaceuticals USA
Sponsor class: INDUSTRY
First posted: 2017-04-27
Enrollment: 1125
Sex: ALL
Minimum age (years): 12
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To evaluate the therapeutic effect of DPSG and Placebo gel in the treatment of acne vulgaris.

Detailed description: A Multi-center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group study comparing DPSG to ACZONE Gel and active treatment to a Placebo control in the treatment of Acne Vulgaris.

Eligibility criteria: Inclusion Criteria:

* Healthy male or non pregnant female aged ≥ 12 years with a clinical diagnosis of acne vulgaris.

Exclusion Criteria:

* Female Subjects who are pregnant, nursing or planning to become pregnant during study participation

Primary outcomes:
measure: Change in inflammatory lesion counts
timeFrame: 12 weeks
measure: Change in non-inflammatory lesion counts
timeFrame: 12 weeks
Secondary outcomes:
measure: Clinical response of success
timeFrame: 12 weeks
Other outcomes:
Locations:
Study officials:
affiliation: http://catawbaresearch.com/contact/
name: Catawba Research
role: STUDY_CHAIR
References:
Clinical trial NCT05178394: Weightlifting Belts and Wrist Straps for Weightlifters
Official title: The Influence of Weightlifting Belts and Wrist Straps on Deadlift Kinematics, Time to Complete a Deadlift and Rating of Perceived Exertion in Male Recreational Weightlifters
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Exercise Movement Techniques
Lead sponsor: The University of Hong Kong
Sponsor class: OTHER
Collaborators: name: Education University of Hong Kong
First posted: 2022-01-05
Enrollment: 20
Sex: MALE
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: Objective: This study examined the effects of weightlifting belts and wrist straps on the kinematics of the deadlift exercise, time to complete a deadlift and rating of perceived exertion (RPE) in male recreational weightlifters.

Methods: Twenty participants used various combinations of belt and straps during a conventional deadlift. The hip and knee flexion, cervical lordosis, thoracic kyphosis and lumbar lordosis angles and time to complete a deadlift were measured using video analysis software. RPE was also recorded.


Eligibility criteria: Inclusion Criteria:

* men
* aged 18 to 30 years
* more than 3 years of weightlifting experience
* have been training at least 4 hours per week
* engage in recreational weightlifting

Exclusion Criteria:

* musculoskeletal disorders (e.g., leg length discrepancies and severe flat feet)
* neurological disorders (e.g., epilepsy)
* spinal problems (e.g., scoliosis)
* upper limb problems (e.g., history of shoulder dislocation, tennis or golf elbow)
* recent injuries that could affect performance
* train regularly for other sports.

Primary outcomes:
measure: Hip flexion angle
timeFrame: Through study completion, an average of two hours
measure: Knee flexion angle
timeFrame: Through study completion, an average of two hours
measure: Cervical lordosis angle
timeFrame: Through study completion, an average of two hours
measure: Thoracic kyphosis angle
timeFrame: Through study completion, an average of two hours
measure: Lumbar lordosis angle
timeFrame: Through study completion, an average of two hours
Secondary outcomes:
measure: Time
timeFrame: Through study completion, an average of two hours
measure: Rating of perceived exertion
timeFrame: Through study completion, an average of two hours
Other outcomes:
Locations:
city: Hong Kong
country: Hong Kong
facility: University of Hong Kong
Study officials:
References:
Clinical trial NCT00235794: An Open Label Exploratory Study in Newly Diagnosed Prostate Cancer Patients
Official title: An Open Label Study of Exploratory Pharmacogenomics and Pharmacologic Effects of Neoadjuvant Oral Temsirolimus in Newly Diagnosed Prostate Cancer Patients Undergoing Radical Prostatectomy Who Have a High Risk of Relapse
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Prostatic Neoplasms
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Sponsor class: INDUSTRY
First posted: 2005-10-10
Enrollment: 50
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: Open-label exloratory pharmacodynamic and pharmacogenomic study to evaluate teh biologic effects of 3 dose levels (1mg, 5 mg, and 15 mg) of temsirolimus administered orally once daily for approximately 4 weeks (+/- 2 weeks) before prostatectomy


Eligibility criteria: Inclusion criteria:

* Histologically confirmed diagnosis of adenocarcinoma of the prostate gland via a minimum of 6 core biopsy samples.
* Subjects must be a candidate for radical prostatectomy
* No evidence of metastatic disease as determined by CT scans and bone scans

  * More criteria apply

Exclusion Criteria:

* Subjects from whom sufficient diagnostic biopsy material is not available for full characterization of the tumor
* Active Infection requiring antibiotic therapy, or serious intercurrent illness, active bleeding, or ongoing urinary tract infection necessitating rapid or emergent surgical resection
* Subjects who have had hormonal injection or implants which will last longer than 6 months

  * More criteria apply

Primary outcomes:
measure: To determine the effects of oral temsirolimus on changes in phosphorylation state of proteins in the mTOR signaling pathway in tumor tissue and on phosphorylation state of mTOR pathway proteins and on global and targeted gene expression pattern PBMCs
Secondary outcomes:
measure: Determine effects of oral temsirolimus on global and targeted gene expression; compare effects in the tumor and PBMCs; obtain preliminary information on potential antitumor effects; evaluate PK using whole blood and tumor tissue.
measure: To evaluate the relationship between PTEN status and the pharmacodynamic/pharmacogenomic effects of temsirolimus and to determine the effects of temsirolimus on changes in protein expression patterns in the plasma
Other outcomes:
Locations:
city: Houston
country: United States
state: Texas
Study officials:
affiliation: Wyeth is now a wholly owned subsidiary of Pfizer
name: Medical Monitor
role: STUDY_DIRECTOR
References:
Clinical trial NCT05984394: Evaluation of Antigen-specific T Cells in Patients With Antisynthetase Syndrome and Interstitial Lung Disease
Official title: Evaluation of Antigen-specific Th1 and T17 Cells, ILC and MAIT in Patients With Antisynthetase Syndrome and Interstitial Lung Disease
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Antisynthetase Syndrome
Lead sponsor: Central Hospital, Nancy, France
Sponsor class: OTHER
First posted: 2023-08-09
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with AS and ILD

Brief summary: Antisynthetase syndrome (AS) is a rare overlapping myositis characterized by cellular and humoral autoimmune responses directed against aminoacyl-tRNA synthetases. Intesrtitial lung disease (ILD) is a leading cause of mortality in antisynthetase syndrome. Recently, antigen-specific IFN-γ+ CD4+ T cells have been identified in bronchoalveolar fluid (BAL) of patients with antisynthetase syndrome and ILD. Elevated levels of IL1β, IL12, IL18, TNFα, IL17A, IL22 have also been detected in peripheral blood of AS patients, especially those with progressive ILD. Implication of innate lymphoid cells (ILC) and mucosal-associated invariant T cells (MAIT) have not yet been studied in patients with AS. Targeted therapies against Th1 and Th17 cells may represent a promising treatment in patients AS patients with ILD.

Investigators suppose that antigen-specific Th1 and Th17 cells, ILC and MAIT at ILD diagnosis are associated with ILD severity at diagnosis and could predict treatment response at 6 months.

The main objective is to study the correlation between BAL antigen-specific Th1 and Th17 cells at ILD diagnosis and clinical evolution after 6 months of treatment according to initial ILD severity.


Eligibility criteria: Inclusion Criteria:

* Patient with new diagnosis of AS with ILD

Exclusion Criteria:

* Patient with ILD differential diagnosis
* Corticosteroid treatment, immunosuppresive or immunomodulatory drugs in the past 3 months before diagnosis

Primary outcomes:
measure: BAL antigen-specific Th1 and Th17 cells
timeFrame: baseline (J0)
measure: FVC relative change
timeFrame: within 6 months after diagnosis
Secondary outcomes:
measure: BAL antigen-specific Th1 and Th17 cells
timeFrame: baseline (J0)
measure: FVC
timeFrame: baseline (J0)
measure: FVC absolute change
timeFrame: within 6 months after diagnosis
measure: Global activity
timeFrame: baseline (J0)
Other outcomes:
measure: BAL ILC
timeFrame: baseline (J0)
measure: BAL MAIT
timeFrame: baseline (J0)
Locations:
city: Dijon
country: France
facility: Bernard Bonnotte
city: Metz
country: France
facility: Julien Campagne
city: Nancy
country: France
facility: Paul Decker
city: Paris
country: France
facility: Olivier Benveniste
city: Reims
country: France
facility: Loïs Bolko
city: Strasbourg
country: France
facility: Alain Meyer
Study officials:
affiliation: CHU NANCY
name: Paul Decker, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06959394: Comparison of the Effectiveness of Therapeutic Ultrasound and Phonophoresis in Chronic Low Back Pain
Official title: Comparison of the Effectiveness of Therapeutic Ultrasound and Phonophoresis Applications in Patients With Chronic Low Back Pain
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Low Back Pain
Lead sponsor: KTO Karatay University
Sponsor class: OTHER
First posted: 2025-05-06
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to evaluate the effects of therapeutic ultrasound and phonophoresis applications on pain, range of motion, flexibility and functional capacity in patients with chronic low back pain. The study is planned as the first scientific study comparing the effectiveness of these two physiotherapy methods in the treatment of chronic low back pain. It is aimed to make national and international publications with the data obtained at the end of the study.

The study will be conducted in a randomised single-blind, placebo-controlled design. 60 patients aged 18-30 years with chronic low back pain will be divided into 3 groups: therapeutic ultrasound (US) application, phonophoresis application and placebo US group. In addition to ultrasound and phonophoresis, TENS, infrared and low back exercises will be applied to all groups as treatment. Pain intensity (VAS), functional status (Oswestry disability index), flexibility (Sit-to-Sit test) and range of motion (goniometric measurements) will be assessed throughout the treatment period.

The study aims to make an important contribution from a clinical and economic point of view, given the increasing prevalence of low back pain worldwide and the need for treatment. The findings may guide the development of future treatment modalities.


Eligibility criteria: Inclusion Criteria:

Individuals with low back pain for more than 3 months and pain intensity more than 5 according to VAS will be included in the study

Exclusion Criteria:

patients who have undergone surgical operations

Primary outcomes:
measure: pain severity
timeFrame: Baseline and after 2 weeks intervation
Secondary outcomes:
measure: functional state
timeFrame: Baseline and after 2 weeks intervation
measure: Flexibility
timeFrame: Baseline and after 2 weeks intervation
measure: range of motion of the joint
timeFrame: Baseline and after 2 weeks intervation
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01231360: The Effect of Exercise Training on Skeletal Muscle Metabolism in Peripheral Artery Disease (PAD)
Official title: The Effect of Exercise Training on Skeletal Muscle Metabolism in Peripheral Artery Disease
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Claudication
Keywords: claudication
peripheral artery disease
PAD
Lead sponsor: Brigham and Women's Hospital
Sponsor class: OTHER
Collaborators: name: American Heart Association
name: Joslin Diabetes Center
First posted: 2010-11-01
Enrollment: 75
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Specific Aim 1: To test the hypothesis that subjects with PAD and intermittent claudication have altered expression of genes that regulate skeletal muscle metabolism.

Specific Aim 2: To test the hypothesis that exercise training improves calf skeletal muscle insulin resistance and genes that regulate skeletal muscle metabolic function in PAD patients with intermittent claudication.


Eligibility criteria: Inclusion Criteria:

* claudication symptoms
* ABI ≤ 0.9 in the symptomatic leg

Exclusion Criteria:

* diabetes
* impaired fasting glucose
* peripheral vascular intervention within the prior six months
* recent unstable angina
* myocardial infarction or stroke within the prior six months
* changes to their HMG-CoA reductase inhibitor (statin)within the past three months
* changes to pentoxifylline and/or cilostazol regimen within the past three months or anticipated to be necessary during the study
* are on Coumadin
* exercise limitations for reasons other than intermittent claudication (such as congestive heart failure, angina, chronic lung disease, or other disorders affecting the limb such as arthritis or neuropathy)
* rest pain or ulcers due to critical limb ischemia
* lower extremity amputation

Primary outcomes:
measure: Expression of genes regulating skeletal muscle metabolism
timeFrame: 3 months
Secondary outcomes:
measure: Additional measures include skeletal muscle glucose uptake, measures of functional capacity, leg blood flow, and quality of life.
timeFrame: 3 months
Other outcomes:
Locations:
city: Boston
country: United States
facility: Brigham and Women's Hospital
state: Massachusetts
Study officials:
affiliation: Brigham and Women's Hospital
name: Reena Pande, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03376360: Functional Medical Imaging Quantization in Prostate Cancer
Official title: Optimization of 18F-choline PET/CT Acquisition in Prostate Cancer: Preliminary Results Concerning the Length of the Acquisition
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Prostate Cancer
Keywords: prostate cancer
Fcholine
positron emission tomography
MRI
Lead sponsor: University Hospital, Brest
Sponsor class: OTHER
First posted: 2017-12-18
Enrollment: 61
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with prostate cancer histologically proven included in Brest University Hospital between 01/07/2012 and 01/10/2015 and underwent F-choline PET/CT and pelvic MRI

Brief summary: Prostate cancer is the most common cancer in men over 50 years old and the third leading cause of cancer death. Because of the variety of prostate cancers, different treatments exist.

Several criteria guide this management in daily practice: PSA level; TNM stage (digital rectal examination, trans-rectal ultrasound and classical visual imaging) and pathological differentiation with the Gleason score, to which can be added other prognostic criteria: growth and doubling time of the serum PSA, number of positive biopsies and percentage of cancer lesions by biopsy.

Functional imaging by PET and MRI is increasingly used in daily clinical practice to characterize prostate cancer, either during initial discovery or during recurrence. In this context, it is the qualitative visual analysis that is mainly used. Quantitative image analysis could add new criteria to guide patient management.

Consequently, the objective of this study were:

* Optimization of 18F-choline PET/CT Acquisition in Prostate Cancer
* Comparison the quantitative parameters obtained by 18F-Choline PET / CT and both perfusion MRI and histological parameters.


Eligibility criteria: Inclusion Criteria:

Patients with prostate cancer histologically proven included in Brest University Hospital between 01/07/2012 and 01/10/2015 and underwent F-choline PET/CT and pelvic MRI Patient consent

Exclusion Criteria:

No lesion on dynamic acquisition on PET/CT and/or on pelvic MRI

Primary outcomes:
measure: correlation between Gleason score and dynamic parameters on PET and MRI
timeFrame: when anatomopathological report is available, an average of 3 months after the PET/CT
Secondary outcomes:
measure: reconstructions on 18F-choline PET
timeFrame: when all 18F-choline PET are performed, an average of 6 months
measure: best "fitting" on PET and MRI
timeFrame: when all MRI are performed, an average of 6 months
measure: comparison between data (PSA, TNM stage, EFS and OS)
timeFrame: 01/05/2017
Other outcomes:
Locations:
city: Brest
country: France
facility: CHRU de Brest
Study officials:
References: